Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success

Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...
PharmaTimes

Santhera reports promising long-term data for AGAMREE in Duchenne muscular dystrophy

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

Sarepta Therapeutics shares plunge after disappointing trial data

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Sarepta Duchenne drugs come up short in confirmatory test

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...

Sarepta Earnings Beat Expectations. Why the Stock Is Down 40%.

The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.
Fierce Pharma

Sarepta pushes for full approval of Duchenne drugs despite missed confirmatory trial goal

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.
pharmaphorum

Sarepta shares slide as DMD treatment woes pile up

Shares in Sarepta Therapeutics lost nearly 40% of their value after the company said a trial designed to confirm the efficacy ...

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare an…

This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes ...

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...
News-Medical.Net on MSN

Smartphones match traditional methods in monitoring patients with muscular dystrophy

Stanford Medicine researchers found that a smartphone could monitor patients with two types of muscular dystrophy as well as ...
The Bakersfield Californian

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults ...

“The approval today of KYGEVVI® (doxecitine and doxribtimine), provides real hope for patients and families living with this devastating disease,” said Angela Lek, PhD, interim Chief Research Officer ...